Lumenis Ltd (LMNS) 13.76 $LMNS Lumenis Launches
Post# of 273333
Posted On: 09/02/2016 7:01:45 PM
Lumenis Ltd (LMNS) 13.76 $LMNS
Lumenis Launches UltraPulse(R) DUO at the ELS Congress and Invites ENT Physicians to Join LINK, A New Revolutionary Platform for Clinical Knowledge Sharing
GlobeNewswire - Wed Jun 08, 3:00AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, launches the UltraPulse DUO CO2 advanced laser platform alongside LINK, a new communication channel for ENT medical professionals, at the 11 congress of the European Laryngological Society (ELS), taking place in Genoa, Italy, from June 8-11, 2016.
LMNS: 13.76 (+0.04)
New Clinical Results on Use of UltraPulse(R) in Treating Patients Suffering from Chronic Radiation Dermatitis to be presented at the French Laser Society Meeting
GlobeNewswire - Thu Jun 02, 8:40AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced that results from the clinical case series analyzing the UltraPulse(R) CO2 laser system will be presented at the upcoming Journee Parisienne Du Laser, a French laser society meeting that will be held in Paris from June 3-4, 2016. The UltraPulse, a high energy short pulsed fractional CO2 laser, was used in a combination of laser treatments on Vietnamese patients suffering from chronic radiation dermatitis -- radiation skin damage or radiation burns -- caused by radiotherapy in treating benign childhood hemangiomas.
LMNS: 13.76 (+0.04)
Lumenis Offers Advanced Surgical Solutions Alongside Comprehensive CO2 Laser Educational Sessions at COSM 2016
GlobeNewswire - Wed May 18, 8:45AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced it will be collaborating with leading educational institutes, residents and fellows to provide training sessions for the state-of-the-art UltraPulse DUO and AcuPulse DUO surgical solutions, at the annual Combined Otolaryngology Spring Meetings (COSM), being held in Chicago from May 18-22, 2016.
LMNS: 13.76 (+0.04)
Lumenis Expands its Urology Portfolio with the Introduction of Three New Additions to the Pulse Family of Holmium Lasers
GlobeNewswire - Fri May 06, 8:00AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of Lumenis Pulse(TM) 100H, Pulse(TM) 50H and Pulse(TM) 30H holmium laser solutions, at the 111th American Urological Association (AUA) Annual Meeting, being held in San Diego from May 6-10, 2016.
LMNS: 13.76 (+0.04)
Lumenis to Present Interim Safety and Efficacy Results of IPL with OPT(TM) for Treating Dry Eye at Major Ophthalmology Meeting
BusinessWire - Thu May 05, 7:06PM CDT
ASCRS Booth #2311-- Lumenis, Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, will present interim results of a multicenter prospective clinical trial designed to study the safety and efficacy of Optimal Pulse Technology (OPT(TM)), the next generation of Intense Pulse Light (IPL) technology, for treating Dry Eye Disease (DED). Data from the trial, being led by Steven J. Dell, MD, of Dell Laser Consultants in Austin, Texas, will be presented at a conference of anterior segment ophthalmologists being held May 6-10 in New Orleans, LA.
LMNS: 13.76 (+0.04)
Lumenis Proudly Announces its Laser Technologies will be the Focus of More than 20 Presentations at the American Society of Laser Medicine and Surgery Conference (ASLMS)
GlobeNewswire - Wed Mar 30, 8:00AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, proudly announced today that the company's laser aesthetic portfolio will be the focus of more than 20 presentations at the American Society of Laser Medicine and Surgery (ASLMS) Annual Conference, being held March 30 to April 3, 2016 at the Hynes Convention Center in Boston, MA. This also includes new data from two clinical studies conducted using the latest breakthrough in hair reduction technology, the LightSheer(R) INFINITY(TM) laser system.
LMNS: 13.76 (+0.04)
Medical Aesthetics Market Forecast to 2020 - Increasing Demand For Minimally Invasive & Non-Invasive Aesthetic Procedures
M2 - Thu Jan 28, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bd5l42/medical) has announced the addition of the "Medical Aesthetics Market by Products, Procedures, & End-Users - Global Forecast to 2020" report to their offering. The market is expected to reach $12,581.9 Million by 2020, at a CAGR of 10.8% from 2015 to 2020. Factors such as the increasing demand of minimally invasive and non-invasive aesthetic procedures, technological advancements in energy based devices, and rapid growth in number of cosmetic procedures are driving the growth of the global medical aesthetics market. However, stringent safety regulations for aesthetic procedures, and a significant number of product recalls are restricting the growth of the global medical aesthetics market. Geographically, North America (comprising the U.S. and Canada) commanded the largest share of 49.0% of the global medical aesthetics market in 2015, followed by Europe. North America will continue to lead in the years to come, owing to rapidly aging and obese population, technological advancements, and growing FDA approvals of devices in the U.S. The growth of the global medical aesthetics market is mainly driven by the growing adoption of minimally invasive and noninvasive aesthetic procedures, aging population, increasing awareness among customers, technological advancements in energy-based devices, rising number of aesthetic procedures, and increasing demand for aesthetic treatments among the male population. However, a stringent safety regulation for aesthetic procedures is a major factor restraining the growth of this market. Growing adoption of home use aesthetic devices and increasing demand for cosmetic treatments in emerging markets are creating opportunities for growth of the medical aesthetics market. Companies Mentioned: - Allergan, Inc. - Cynosure, Inc. - Galderma S.A. (Switzerland) - Lumenis Ltd. - Mentor Worldwide LLC - PhotoMedex, Inc. - Solta Medical, Inc. - Syneron Medical, Ltd. - ZELTIQ Aesthetics, Inc. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Market, By Product 7 Medical Aesthetics Market, By End User 8 Medical Aesthetics Market, By Procedure 9 Global Medical Aesthetics Market, By Region 10 Competitive Landscape 11 Company Profiles For more information visit http://www.researchandmarkets.com/research/bd5l42/medical
ELOS: 6.52 (-0.08), AGN: 235.96 (-1.80), ZLTQ: 38.07 (-0.14), CYNO: 51.59 (-0.36), LMNS: 13.76 (+0.04), PHMD: 0.22 (-0.02)
GlucoTrack® Maker Hires Chief Operating Officer
PR Newswire - Tue Jan 12, 8:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that it has hired Eran Cohen as its Chief Operating Officer (COO).
ALGN: 95.78 (+2.02), LMNS: 13.76 (+0.04)
ENT and Bronchoscopy Devices - Global Strategic Business Report 2015-2020 - Rising Incidence of ENT and Respiratory Disorders - A Grim Reality Driving Growth
M2 - Mon Dec 07, 10:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5tclnh/ent_and) has announced the addition of the "ENT and Bronchoscopy Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for ENT and Bronchoscopy Devices in US$ Thousand by the following Product Types: ENT Devices, and Bronchoscopy Devices. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 80 companies including many key and niche players such as - Boston Scientific Corporation (USA) - Broncus Technologies, Inc (USA) - Carl Zeiss Meditec AG (Germany) - Conmed Corporation (USA) - Hoya Corporation (Japan) - PENTAX Medical (Japan) - Intersect ENT Inc. (USA) - Karl Storz GmbH & Co. KG (Germany) - Lumenis Ltd (Israel) - Medtronic, Inc (USA) - Olympus Corporation (Japan) - Richard Wolf GmbH (Germany) - Smith & Nephew plc (USA) - Stryker Corporation (USA) - Welch Allyn, Inc (USA) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET TRENDS, GROWTH DRIVERS, & CHALLENGES 3. PRODUCT OVERVIEW 4. PRODUCT INTRODUCTIONS, INNOVATIONS & APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 80 (including Divisions/Subsidiaries - 94) - The United States (43) - Canada (1) - Japan (5) - Europe (37) - - France (2) - - Germany (23) - - The United Kingdom (6) - - Rest of Europe (6) - Asia-Pacific (Excluding Japan) (6) - Latin America (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5tclnh/ent_and
XENT: 15.98 (+0.28), BSX: 24.26 (-0.07), SNN: 33.47 (+0.77), MDT: 87.32 (+0.34), LMNS: 13.76 (+0.04), SYK: 115.60 (+0.37)
Lumenis Expands Its Portfolio of Gynecology Solutions With the New UltraPulse(R) DUO(TM) for Fertility-Related Disorders and FemTouch(TM) for Improved Vaginal Health
GlobeNewswire - Fri Nov 13, 8:00AM CST
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today that the company will showcase its new UltraPulse DUO CO2 laser system and the new FemTouch solution at the American Association of Gynecologic Laparoscopists (AAGL) Annual Meeting, taking place November 15-19, 2015 in Las Vegas, Nevada.
LMNS: 13.76 (+0.04)
Lumenis UltraPulse(R) Technology is Being Used to Treat Kim Phuc "The Girl in the Picture"
GlobeNewswire - Thu Nov 05, 9:18AM CST
Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmology applications announced today that the company's UltraPulse laser is being used in the treatment of the type of scars presented by Kim Phuc, a survivor of a Vietnam War bombing in 1972. It was chosen to be used for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars.
LMNS: 13.76 (+0.04)
Lumenis Acquires Israeli-Based Pollogen Strengthening and Expanding Its Aesthetic Division
GlobeNewswire - Mon Nov 02, 9:00AM CST
Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, announced today that the company has completed the acquisition of Pollogen Ltd.
LMNS: 13.76 (+0.04)
North American Ophthalmology Surgery Devices Market by Types by End-users - Forecast to 2019
PR Newswire - Tue Oct 27, 8:42PM CDT
The global ophthalmology glaucoma surgery devices market is estimated to grow at a CAGR of 8.4% from 2014 to 2019. The North American region accounted for the largest share of this market, and is projected to grow at a CAGR of 7.8% during the given forecast period. The ophthalmology glaucoma surgery device market holds a high potential for growth in the coming years owing to the increasing strategic expansion of companies, the growing aging population, and the rising incidence of eye disorders. However, general lack of awareness among people about eye disorders and poor primary healthcare infrastructure, along with lack of healthcare insurance, are the major factors that may restrain the growth of the global ophthalmology glaucoma surgery device market in the coming years.In this report, the ophthalmology glaucoma surgery devices market has been broadly classified on the basis of end-user, type, and geography. Geographically, the market has been segmented into North America, Europe, Asia, and Rest of the World (RoW), wherein the North American market commanded the largest share of 45.1% of the global ophthalmology glaucoma surgery device market in 2014, followed by the European market. The report has profiled the leading players of this market, along with the developments (new product launches, partnerships, agreements, collaborations, and joint ventures) done by the companies over the past few years and strategies adopted by them to sustain and strengthen their positions in the global ophthalmology glaucoma surgery device market.
ABT: 42.09 (-0.21), LMNS: 13.76 (+0.04)
Global Glaucoma Surgery Devices Market to 2019 by Type (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems), by End User (Private Eye Clinics, Hospitals), by Geography
PR Newswire Europe - Wed Oct 14, 2:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hkf3n4/global_glaucoma [http://www.researchandmarkets.com/research/hkf3n4/global_glaucoma]) has announced the addition of the "Global Glaucoma Surgery Devices Market by Type (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems), by End User (Private Eye Clinics, Hospitals), by Geography - Analysis and Forecast to 2019" [http://www.researchandmarkets.com/research/hkf3n4/global_glaucoma] report to their offering.
ABT: 42.09 (-0.21), LMNS: 13.76 (+0.04)
Lumenis and XIO Complete Merger
GlobeNewswire - Mon Oct 12, 7:30AM CDT
Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications announced today that the previously reported merger transaction with an affiliate of XIO Group has been completed. Pursuant to the transaction, shareholders will receive the merger consideration of $14 per share in cash. Trading of Lumenis' ordinary B shares on NASDAQ Global Select Market has ceased.
LMNS: 13.76 (+0.04)
Global Glaucoma Surgery Devices (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems) Market 2015-2019
M2 - Thu Oct 08, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrqff7/global_glaucoma) has announced the addition of the "Global Glaucoma Surgery Devices Market by Type (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems), by End User (Private Eye Clinics, Hospitals), by Geography - Analysis and Forecast to 2019" report to their offering. The North American region accounted for the largest share of this market, and is projected to grow at a CAGR of 7.8% during the given forecast period. The glaucoma surgery device market holds a high potential for growth in the coming years owing to the increasing strategic expansion of companies, the growing aging population, and the rising incidence of eye disorders. However, general lack of awareness among people about eye disorders and poor primary healthcare infrastructure, along with lack of healthcare insurance, are the major factors that may restrain the growth of the global glaucoma surgery device market in the coming years. The report has profiled the leading players of this market, along with the developments (new product launches, partnerships, agreements, collaborations, and joint ventures) done by the companies over the past few years and strategies adopted by them to sustain and strengthen their positions in the global glaucoma surgery device market. The key players in the global glaucoma surgery device market are Abbott Laboratories (U.S.), Alcon, Inc. (Switzerland), Carl Zeiss Meditec AG (Germany), Nidek Co., Ltd. (U.S.), Lumenis Ltd. (Israel), Ellex Medical Lasers Ltd. (Australia), and Iridex Corporation (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Glaucoma Surgery Devices By Type 6 Glaucoma Surgery Devices By End-User 7 Glaucoma Surgery Devices By Geography 8 Glaucoma Surgery Devices : Competitive Landscape 9 Glaucoma Surgery Devices By Company - Abbott Laboratories - Alcon, Inc. - Carl Zeiss Meditec Ag - Ellex Medical Lasers Limited - Iridex Corporation - Lumenis Ltd. - Nidek Co., Ltd. For more information visit http://www.researchandmarkets.com/research/qr...l_glaucoma
ABT: 42.09 (-0.21), LMNS: 13.76 (+0.04)
Lumenis Introduces the New Pulse(TM) 100H and Pulse(TM) 50H Holmium Laser Systems* Designed to Treat Any Size of Prostate and Any Size and Type of Stone
Thomson Reuters ONE - Thu Oct 01, 3:00AM CDT
LONDON, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of Lumenis Pulse(TM) 100H and Lumenis Pulse(TM) 50H at the 33rd World Congress of Endourology (WCE), taking place October 1 - 4, 2015 in London, UK.
LMNS: 13.76 (+0.04)
Lumenis and XIO Proceed to Closing of Merger
GlobeNewswire - Mon Sep 21, 8:10AM CDT
Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications, and XIO Group jointly announced today that the merger transaction under which XIO Group will acquire Lumenis for $14.00 per share in cash, is expected to close by October 18, 2015.
LMNS: 13.76 (+0.04)
Lumenis Announces UltraPulse(R) With SCAAR FX(TM) Clinical Data to be Presented at the 16th European Burns Association Congress
Thomson Reuters ONE - Wed Sep 16, 2:00AM CDT
Attending the Conference for the First Time, Lumenis Shares New Standard of Care Laser Solutions and Therapies With the Burn Treatment Community
LMNS: 13.76 (+0.04)
Lumenis Announces Results of Special Shareholders' Meeting
GlobeNewswire - Mon Aug 03, 3:05PM CDT
Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications, announced that at the special shareholders' meeting held today in Yokneam, Israel, the shareholders of Lumenis approved each of the proposals brought before the shareholders, including the merger proposal pursuant to which, by way of statutory merger, Lumenis will become a wholly-owned subsidiary of an Israeli company that is, indirectly, wholly- owned by XIO Fund I LP, all as described in the Proxy Statement, dated July 9, 2015, that was annexed as Exhibit 99.1 to Lumenis' Report of Foreign Private Issuer on Form 6-K that was furnished to the Securities and Exchange Commission on July 9, 2015.
LMNS: 13.76 (+0.04)
Lumenis Launches UltraPulse(R) DUO at the ELS Congress and Invites ENT Physicians to Join LINK, A New Revolutionary Platform for Clinical Knowledge Sharing
GlobeNewswire - Wed Jun 08, 3:00AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, launches the UltraPulse DUO CO2 advanced laser platform alongside LINK, a new communication channel for ENT medical professionals, at the 11 congress of the European Laryngological Society (ELS), taking place in Genoa, Italy, from June 8-11, 2016.
LMNS: 13.76 (+0.04)
New Clinical Results on Use of UltraPulse(R) in Treating Patients Suffering from Chronic Radiation Dermatitis to be presented at the French Laser Society Meeting
GlobeNewswire - Thu Jun 02, 8:40AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced that results from the clinical case series analyzing the UltraPulse(R) CO2 laser system will be presented at the upcoming Journee Parisienne Du Laser, a French laser society meeting that will be held in Paris from June 3-4, 2016. The UltraPulse, a high energy short pulsed fractional CO2 laser, was used in a combination of laser treatments on Vietnamese patients suffering from chronic radiation dermatitis -- radiation skin damage or radiation burns -- caused by radiotherapy in treating benign childhood hemangiomas.
LMNS: 13.76 (+0.04)
Lumenis Offers Advanced Surgical Solutions Alongside Comprehensive CO2 Laser Educational Sessions at COSM 2016
GlobeNewswire - Wed May 18, 8:45AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced it will be collaborating with leading educational institutes, residents and fellows to provide training sessions for the state-of-the-art UltraPulse DUO and AcuPulse DUO surgical solutions, at the annual Combined Otolaryngology Spring Meetings (COSM), being held in Chicago from May 18-22, 2016.
LMNS: 13.76 (+0.04)
Lumenis Expands its Urology Portfolio with the Introduction of Three New Additions to the Pulse Family of Holmium Lasers
GlobeNewswire - Fri May 06, 8:00AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of Lumenis Pulse(TM) 100H, Pulse(TM) 50H and Pulse(TM) 30H holmium laser solutions, at the 111th American Urological Association (AUA) Annual Meeting, being held in San Diego from May 6-10, 2016.
LMNS: 13.76 (+0.04)
Lumenis to Present Interim Safety and Efficacy Results of IPL with OPT(TM) for Treating Dry Eye at Major Ophthalmology Meeting
BusinessWire - Thu May 05, 7:06PM CDT
ASCRS Booth #2311-- Lumenis, Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, will present interim results of a multicenter prospective clinical trial designed to study the safety and efficacy of Optimal Pulse Technology (OPT(TM)), the next generation of Intense Pulse Light (IPL) technology, for treating Dry Eye Disease (DED). Data from the trial, being led by Steven J. Dell, MD, of Dell Laser Consultants in Austin, Texas, will be presented at a conference of anterior segment ophthalmologists being held May 6-10 in New Orleans, LA.
LMNS: 13.76 (+0.04)
Lumenis Proudly Announces its Laser Technologies will be the Focus of More than 20 Presentations at the American Society of Laser Medicine and Surgery Conference (ASLMS)
GlobeNewswire - Wed Mar 30, 8:00AM CDT
Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, proudly announced today that the company's laser aesthetic portfolio will be the focus of more than 20 presentations at the American Society of Laser Medicine and Surgery (ASLMS) Annual Conference, being held March 30 to April 3, 2016 at the Hynes Convention Center in Boston, MA. This also includes new data from two clinical studies conducted using the latest breakthrough in hair reduction technology, the LightSheer(R) INFINITY(TM) laser system.
LMNS: 13.76 (+0.04)
Medical Aesthetics Market Forecast to 2020 - Increasing Demand For Minimally Invasive & Non-Invasive Aesthetic Procedures
M2 - Thu Jan 28, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bd5l42/medical) has announced the addition of the "Medical Aesthetics Market by Products, Procedures, & End-Users - Global Forecast to 2020" report to their offering. The market is expected to reach $12,581.9 Million by 2020, at a CAGR of 10.8% from 2015 to 2020. Factors such as the increasing demand of minimally invasive and non-invasive aesthetic procedures, technological advancements in energy based devices, and rapid growth in number of cosmetic procedures are driving the growth of the global medical aesthetics market. However, stringent safety regulations for aesthetic procedures, and a significant number of product recalls are restricting the growth of the global medical aesthetics market. Geographically, North America (comprising the U.S. and Canada) commanded the largest share of 49.0% of the global medical aesthetics market in 2015, followed by Europe. North America will continue to lead in the years to come, owing to rapidly aging and obese population, technological advancements, and growing FDA approvals of devices in the U.S. The growth of the global medical aesthetics market is mainly driven by the growing adoption of minimally invasive and noninvasive aesthetic procedures, aging population, increasing awareness among customers, technological advancements in energy-based devices, rising number of aesthetic procedures, and increasing demand for aesthetic treatments among the male population. However, a stringent safety regulation for aesthetic procedures is a major factor restraining the growth of this market. Growing adoption of home use aesthetic devices and increasing demand for cosmetic treatments in emerging markets are creating opportunities for growth of the medical aesthetics market. Companies Mentioned: - Allergan, Inc. - Cynosure, Inc. - Galderma S.A. (Switzerland) - Lumenis Ltd. - Mentor Worldwide LLC - PhotoMedex, Inc. - Solta Medical, Inc. - Syneron Medical, Ltd. - ZELTIQ Aesthetics, Inc. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Market, By Product 7 Medical Aesthetics Market, By End User 8 Medical Aesthetics Market, By Procedure 9 Global Medical Aesthetics Market, By Region 10 Competitive Landscape 11 Company Profiles For more information visit http://www.researchandmarkets.com/research/bd5l42/medical
ELOS: 6.52 (-0.08), AGN: 235.96 (-1.80), ZLTQ: 38.07 (-0.14), CYNO: 51.59 (-0.36), LMNS: 13.76 (+0.04), PHMD: 0.22 (-0.02)
GlucoTrack® Maker Hires Chief Operating Officer
PR Newswire - Tue Jan 12, 8:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with Type 2 diabetes and pre-diabetics, announced that it has hired Eran Cohen as its Chief Operating Officer (COO).
ALGN: 95.78 (+2.02), LMNS: 13.76 (+0.04)
ENT and Bronchoscopy Devices - Global Strategic Business Report 2015-2020 - Rising Incidence of ENT and Respiratory Disorders - A Grim Reality Driving Growth
M2 - Mon Dec 07, 10:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/5tclnh/ent_and) has announced the addition of the "ENT and Bronchoscopy Devices - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for ENT and Bronchoscopy Devices in US$ Thousand by the following Product Types: ENT Devices, and Bronchoscopy Devices. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 80 companies including many key and niche players such as - Boston Scientific Corporation (USA) - Broncus Technologies, Inc (USA) - Carl Zeiss Meditec AG (Germany) - Conmed Corporation (USA) - Hoya Corporation (Japan) - PENTAX Medical (Japan) - Intersect ENT Inc. (USA) - Karl Storz GmbH & Co. KG (Germany) - Lumenis Ltd (Israel) - Medtronic, Inc (USA) - Olympus Corporation (Japan) - Richard Wolf GmbH (Germany) - Smith & Nephew plc (USA) - Stryker Corporation (USA) - Welch Allyn, Inc (USA) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET TRENDS, GROWTH DRIVERS, & CHALLENGES 3. PRODUCT OVERVIEW 4. PRODUCT INTRODUCTIONS, INNOVATIONS & APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 80 (including Divisions/Subsidiaries - 94) - The United States (43) - Canada (1) - Japan (5) - Europe (37) - - France (2) - - Germany (23) - - The United Kingdom (6) - - Rest of Europe (6) - Asia-Pacific (Excluding Japan) (6) - Latin America (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5tclnh/ent_and
XENT: 15.98 (+0.28), BSX: 24.26 (-0.07), SNN: 33.47 (+0.77), MDT: 87.32 (+0.34), LMNS: 13.76 (+0.04), SYK: 115.60 (+0.37)
Lumenis Expands Its Portfolio of Gynecology Solutions With the New UltraPulse(R) DUO(TM) for Fertility-Related Disorders and FemTouch(TM) for Improved Vaginal Health
GlobeNewswire - Fri Nov 13, 8:00AM CST
Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today that the company will showcase its new UltraPulse DUO CO2 laser system and the new FemTouch solution at the American Association of Gynecologic Laparoscopists (AAGL) Annual Meeting, taking place November 15-19, 2015 in Las Vegas, Nevada.
LMNS: 13.76 (+0.04)
Lumenis UltraPulse(R) Technology is Being Used to Treat Kim Phuc "The Girl in the Picture"
GlobeNewswire - Thu Nov 05, 9:18AM CST
Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmology applications announced today that the company's UltraPulse laser is being used in the treatment of the type of scars presented by Kim Phuc, a survivor of a Vietnam War bombing in 1972. It was chosen to be used for its effectiveness in laser scar revision therapy that is needed to penetrate deep into the thick scars.
LMNS: 13.76 (+0.04)
Lumenis Acquires Israeli-Based Pollogen Strengthening and Expanding Its Aesthetic Division
GlobeNewswire - Mon Nov 02, 9:00AM CST
Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, announced today that the company has completed the acquisition of Pollogen Ltd.
LMNS: 13.76 (+0.04)
North American Ophthalmology Surgery Devices Market by Types by End-users - Forecast to 2019
PR Newswire - Tue Oct 27, 8:42PM CDT
The global ophthalmology glaucoma surgery devices market is estimated to grow at a CAGR of 8.4% from 2014 to 2019. The North American region accounted for the largest share of this market, and is projected to grow at a CAGR of 7.8% during the given forecast period. The ophthalmology glaucoma surgery device market holds a high potential for growth in the coming years owing to the increasing strategic expansion of companies, the growing aging population, and the rising incidence of eye disorders. However, general lack of awareness among people about eye disorders and poor primary healthcare infrastructure, along with lack of healthcare insurance, are the major factors that may restrain the growth of the global ophthalmology glaucoma surgery device market in the coming years.In this report, the ophthalmology glaucoma surgery devices market has been broadly classified on the basis of end-user, type, and geography. Geographically, the market has been segmented into North America, Europe, Asia, and Rest of the World (RoW), wherein the North American market commanded the largest share of 45.1% of the global ophthalmology glaucoma surgery device market in 2014, followed by the European market. The report has profiled the leading players of this market, along with the developments (new product launches, partnerships, agreements, collaborations, and joint ventures) done by the companies over the past few years and strategies adopted by them to sustain and strengthen their positions in the global ophthalmology glaucoma surgery device market.
ABT: 42.09 (-0.21), LMNS: 13.76 (+0.04)
Global Glaucoma Surgery Devices Market to 2019 by Type (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems), by End User (Private Eye Clinics, Hospitals), by Geography
PR Newswire Europe - Wed Oct 14, 2:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hkf3n4/global_glaucoma [http://www.researchandmarkets.com/research/hkf3n4/global_glaucoma]) has announced the addition of the "Global Glaucoma Surgery Devices Market by Type (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems), by End User (Private Eye Clinics, Hospitals), by Geography - Analysis and Forecast to 2019" [http://www.researchandmarkets.com/research/hkf3n4/global_glaucoma] report to their offering.
ABT: 42.09 (-0.21), LMNS: 13.76 (+0.04)
Lumenis and XIO Complete Merger
GlobeNewswire - Mon Oct 12, 7:30AM CDT
Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications announced today that the previously reported merger transaction with an affiliate of XIO Group has been completed. Pursuant to the transaction, shareholders will receive the merger consideration of $14 per share in cash. Trading of Lumenis' ordinary B shares on NASDAQ Global Select Market has ceased.
LMNS: 13.76 (+0.04)
Global Glaucoma Surgery Devices (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems) Market 2015-2019
M2 - Thu Oct 08, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrqff7/global_glaucoma) has announced the addition of the "Global Glaucoma Surgery Devices Market by Type (Glaucoma Drainage, Implants & Stents, Glaucoma Laser Devices, Glaucoma Systems), by End User (Private Eye Clinics, Hospitals), by Geography - Analysis and Forecast to 2019" report to their offering. The North American region accounted for the largest share of this market, and is projected to grow at a CAGR of 7.8% during the given forecast period. The glaucoma surgery device market holds a high potential for growth in the coming years owing to the increasing strategic expansion of companies, the growing aging population, and the rising incidence of eye disorders. However, general lack of awareness among people about eye disorders and poor primary healthcare infrastructure, along with lack of healthcare insurance, are the major factors that may restrain the growth of the global glaucoma surgery device market in the coming years. The report has profiled the leading players of this market, along with the developments (new product launches, partnerships, agreements, collaborations, and joint ventures) done by the companies over the past few years and strategies adopted by them to sustain and strengthen their positions in the global glaucoma surgery device market. The key players in the global glaucoma surgery device market are Abbott Laboratories (U.S.), Alcon, Inc. (Switzerland), Carl Zeiss Meditec AG (Germany), Nidek Co., Ltd. (U.S.), Lumenis Ltd. (Israel), Ellex Medical Lasers Ltd. (Australia), and Iridex Corporation (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Glaucoma Surgery Devices By Type 6 Glaucoma Surgery Devices By End-User 7 Glaucoma Surgery Devices By Geography 8 Glaucoma Surgery Devices : Competitive Landscape 9 Glaucoma Surgery Devices By Company - Abbott Laboratories - Alcon, Inc. - Carl Zeiss Meditec Ag - Ellex Medical Lasers Limited - Iridex Corporation - Lumenis Ltd. - Nidek Co., Ltd. For more information visit http://www.researchandmarkets.com/research/qr...l_glaucoma
ABT: 42.09 (-0.21), LMNS: 13.76 (+0.04)
Lumenis Introduces the New Pulse(TM) 100H and Pulse(TM) 50H Holmium Laser Systems* Designed to Treat Any Size of Prostate and Any Size and Type of Stone
Thomson Reuters ONE - Thu Oct 01, 3:00AM CDT
LONDON, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced the launch of Lumenis Pulse(TM) 100H and Lumenis Pulse(TM) 50H at the 33rd World Congress of Endourology (WCE), taking place October 1 - 4, 2015 in London, UK.
LMNS: 13.76 (+0.04)
Lumenis and XIO Proceed to Closing of Merger
GlobeNewswire - Mon Sep 21, 8:10AM CDT
Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications, and XIO Group jointly announced today that the merger transaction under which XIO Group will acquire Lumenis for $14.00 per share in cash, is expected to close by October 18, 2015.
LMNS: 13.76 (+0.04)
Lumenis Announces UltraPulse(R) With SCAAR FX(TM) Clinical Data to be Presented at the 16th European Burns Association Congress
Thomson Reuters ONE - Wed Sep 16, 2:00AM CDT
Attending the Conference for the First Time, Lumenis Shares New Standard of Care Laser Solutions and Therapies With the Burn Treatment Community
LMNS: 13.76 (+0.04)
Lumenis Announces Results of Special Shareholders' Meeting
GlobeNewswire - Mon Aug 03, 3:05PM CDT
Lumenis Ltd. (NASDAQ:LMNS), the world's largest energy-based medical company for surgical, ophthalmology and aesthetic applications, announced that at the special shareholders' meeting held today in Yokneam, Israel, the shareholders of Lumenis approved each of the proposals brought before the shareholders, including the merger proposal pursuant to which, by way of statutory merger, Lumenis will become a wholly-owned subsidiary of an Israeli company that is, indirectly, wholly- owned by XIO Fund I LP, all as described in the Proxy Statement, dated July 9, 2015, that was annexed as Exhibit 99.1 to Lumenis' Report of Foreign Private Issuer on Form 6-K that was furnished to the Securities and Exchange Commission on July 9, 2015.
LMNS: 13.76 (+0.04)
(0)
(0)